Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Korea, republic of
  4. Korea Stock Exchange
  5. Samsung Biologics Co.,Ltd.
  6. Summary
    A207940   KR7207940008

SAMSUNG BIOLOGICS CO.,LTD.

(A207940)
  Report
 SummaryChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   End-of-day quote. End-of-day quote Korea Stock Exchange
09/15/2021 09/16/2021 09/17/2021 09/23/2021 09/24/2021 Date
936000 916000 933000 920000 922000 Last
76766 55857 71228 50033 46522 Volume
+2.52% -2.14% +1.86% -1.39% +0.22% Change
Estimated financial data (e)
Sales 2021 1 482 B 1,26 B 1,26 B
Net income 2021 396 B 0,34 B 0,34 B
Net Debt 2021 140 B 0,12 B 0,12 B
P/E ratio 2021 154x
Yield 2021 -
Sales 2022 1 718 B 1,46 B 1,46 B
Net income 2022 483 B 0,41 B 0,41 B
Net Debt 2022 5,68 B 0,00 B 0,00 B
P/E ratio 2022 126x
Yield 2022 -
Capitalization 61 004 B 51 643 M 51 670 M
EV / Sales 2021 41,2x
EV / Sales 2022 35,5x
Nbr of Employees 2 886
Free-Float 25,0%
More Financials
Company
Samsung Biologics Co Ltd is a Korea-based company primarily engaged in development, manufacture and distribution of biological products. The Company, as a contract manufacturing organization (CMO), mainly develops and manufactures antibody drugs used for treatment of cancer, autoimmune disease, diabetes and chronic diseases. It also provides cell line development and process development services. The Company... 
Sector
Pharmaceuticals
Calendar
-
More about the company
Ratings of Samsung Biologics Co.,Ltd.
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
B-
More Ratings
All news about SAMSUNG BIOLOGICS CO.,LTD.
09/22Samsung Biologics showcases its newest CDO process platform, S-CellerateÖ, at BPI 2021,..
CI
09/20Biogen, Samsung Bioepis Get FDA OK for Lucentis Biosimilar
DJ
09/17South Korea Stocks Rise on Upbeat August US Retail Sales; Samsung Electronics Adds 1%
MT
09/13Samsung Biologics Joins Frontier 1.5D Project as Part of 2050 Carbon Neutral Initiative
CI
08/27KOSPI COMPOSITE INDEX : South Korea Stocks Gain Marginally as Investors' Await US Fed Chie..
MT
08/26MARKET CHATTER : Samsung Biologics Eyes Inaugural Public Bond Offering
MT
08/24SAMSUNG BIOLOGICS : European Commission Grants Marketing Approval to Samsung Bioepis' Luce..
MT
08/24Samsung to invest $206 bln by 2023 for post-pandemic growth
RE
08/19S.Korean stocks end at over four-month low on taper, virus fears
RE
08/19SAMSUNG BIOLOGICS : leader returns to court a week after being released
AQ
08/16MARKET CHATTER : Samsung Bioepis' Biosimilar Sales Globally Surge 30% in H1
MT
08/05S.Korea pledges nearly $2 bln to become major COVID-19 vaccine producer
RE
07/28SAMSUNG BIOLOGICS' : Net Profit Surges over 130% in Q2
MT
07/27Samsung Biologics Co.,Ltd. Reports Earnings Results for the Second Quarter Ended June 3..
CI
07/27Samsung Biologics Co.,Ltd. Provides Dividend Guidance for the Year 2021
CI
More news
News in other languages on SAMSUNG BIOLOGICS CO.,LTD.
09/17Les actions sud-coréennes augmentent en raison de l'optimisme des ventes au détail aux ..
08/27Les actions sud-coréennes progressent légèrement alors que les investisseurs attendent ..
08/24Samsung lance un plan d'investissement de 175 milliards d'euros sur trois ans
08/24Samsung invertirá 206.000 millones de dólares en los próximos tres años
08/24Samsung va investir 206 milliards de dollars en trois ans
More news
Analyst Recommendations on SAMSUNG BIOLOGICS CO.,LTD.
More recommendations
Chart SAMSUNG BIOLOGICS CO.,LTD.
Duration : Period :
Samsung Biologics Co.,Ltd. Technical Analysis Chart | A207940 | KR7207940008 | MarketScreener
Technical analysis trends SAMSUNG BIOLOGICS CO.,LTD.
Short TermMid-TermLong Term
TrendsNeutralBullishBullish
Income Statement Evolution
Consensus
Mean consensus -
Number of Analysts 0
Last Close Price 922 000,00 
Average target price
Spread / Average Target -
EPS Revisions
Managers and Directors
John Chongbo Rim President, Chief Executive Officer & Director
Tae-Han Kim Chairman
Yong-Ho An Managing Director & Head-Process Technology
Hyung-Woo Moon Head-Compliance Support
Seok-Woo Jung Independent Director
Sector and Competitors